Aurora Cannabis
ACB | NASDAQ
$4.61
-$0.33 (-6.68%)
At close: Nov 16, 2026, 4:00 PM ET
$4.55
-$0.06 (-1.30%)
After-hours:
Nov 16, 2026, 7:34 PM ET
Aurora Cannabis Company Profile
Company profile explainedCompany Profile
Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.
Key Executives
| Name | Position |
|---|---|
| Miguel Martin | Chief Executive Officer & Executive Chairman |
| Simona King | Chief Financial Officer |
| Alex Miller | Executive Vice President of Operations & Supply Chain |
| David Aird | Executive Vice President of Information Technology |
| Kerry Miller | Managing Director for Australia & New Zealand |
| Kevin Niland | Senior Director of Strategic Finance - Global FP&A and Investor Relations |
| Lori Schick | Executive Vice President of Human Resources |
| Michelle Lefler | Vice President of Communications & Public Relations |
| Nathalie Clark | Executive Vice President, General Counsel & Corporate Secretary |
| Rick Savone | Senior Vice President of Global Government Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 6-K | Filing |
| Oct 26, 2026 | SC14D9F/A | [Amend] Filing |
| Oct 26, 2026 | 6-K | Filing |
| Oct 15, 2026 | SC14D9F/A | [Amend] Filing |
| Oct 14, 2026 | 6-K | Filing |
| Oct 08, 2026 | 6-K | Filing |
| Oct 07, 2026 | 6-K | Filing |
| Oct 06, 2026 | SC14D9F/A | [Amend] Filing |
| Oct 06, 2026 | SC14D9F/A | [Amend] Filing |
| Oct 06, 2026 | SC14D1F/A | [Amend] Filing |
Aurora Cannabis
| Country | Canada |
| IPO Date | Jul 15, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,028 |
| CEO | Miguel Martin |
Stock Details
| Ticker Symbol | ACB |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001683541 |
| CUSIP Number | 05156X850 |
| ISIN Number | CA05156X8504 |
| SIC Code | 2833 |
Add to Watchlist
Select watchlists to add or remove ACB